Sign in to view Artavazd’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Cambridge, Massachusetts, United States
Contact Info
Sign in to view Artavazd’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
2K followers
500+ connections
Sign in to view Artavazd’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Artavazd
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Artavazd
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Sign in to view Artavazd’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Experience & Education
-
Qiming Venture Partners USA
*********
-
********** ** *****, ****** ****** ** ********
************ ** *********
-
******** *******
******** *********** ****
-
********** ** *****, ****** ****** ** ********
****** ** ********** - ***
-
**. ******* *******
******** ** ******* (*.*.)
View Artavazd’s full experience
See their title, tenure and more.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View Artavazd’s full profile
Sign in
Stay updated on your professional world
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
People also viewed
-
Alex Loftis
Senior Associate at Vida Ventures
Los Angeles, CAConnect -
Alim Ladha
Cambridge, MAConnect -
Aniqa Tasnim
Associate at 5AM Ventures
Boston, MAConnect -
David K. Yang
San Francisco Bay AreaConnect -
Lauren Mifflin
Boston, MAConnect -
Travis Hughes MD, PhD, MPH
Digitalis Ventures - Life Sciences Investment Team
Cambridge, MAConnect -
Harim Won
Greater PhiladelphiaConnect -
Linda T. Vo, PhD
Boston, MAConnect -
Will McConnell
Principal at Qiming Venture Partners USA
San Francisco, CAConnect -
James Buxton M.D.
New York, NYConnect -
Jason Wang
Palo Alto, CAConnect -
Roman Camarda
San Francisco, CAConnect -
Rebecca Silberman
Cambridge, MAConnect -
Suan Tuang, M.D., Ph.D.
Greater BostonConnect -
Shoman Kasbekar
United StatesConnect -
Nil Gural
New York, NYConnect -
Patrick Lundgren
Boston, MAConnect -
Pablo Lubroth
New York, NYConnect -
Amanda Chen
Investment @ Vertex Ventures HC
Cambridge, MAConnect -
Anna French, DPhil
Cambridge, MAConnect
Explore more posts
-
Varun Aggarwala
Have things really changed in the last 200 years? Earlier we were a bottomless pit for men to fight British wars and run their colonies, and now we are reduced to graduating talent for top innovative Western R&D giants. Will we ever build anything in India with cutting edge R&D? Will our research move the needle in any field in India? The world is racing ahead, but have we evolved psychologically from centuries of colonization & humiliation to control our own destiny. I know some of the amazing folks at Xaira. Prof. Baker is the real deal and his research (I have tracked it for the last 14 years) and ambitions, alongwith available technology (he was always ahead of existing tech), can revolutionize the entire drug design industry.
9
-
Thomas Wilckens (托馬斯)
CytoReason and the Crohn’s & Colitis Foundation Forge Groundbreaking Data Collaboration to Advance IBD Research Kudos Shai Shen-Orr David H. CytoReason, a pioneer in developing computational disease models for drug development, today announced a strategic collaboration with the Crohn’s & Colitis Foundation. The collaboration aims to empower CytoReason’s analytical capabilities with the Foundation’s IBD Plexus® real-world data platform. This collaboration has the potential to accelerate new discoveries with superior data integration and improve the precision and effectiveness of drug development in inflammatory bowel disease (IBD).As part of the collaboration, the Foundation’s IBD Plexus® real-world data platform, comprising thousands of patient intestinal biopsies and comprehensive real-world data, will be integrated into CytoReason’s pre-computed disease model platform. The combination of IBD Plexus® real-world data with CytoReason’s advanced computational capabilities will enable fine characterization of disease subtypes, positioning of treatments and combination therapies throughout disease subtypes, and generation of blood-based biomarkers to facilitate clinical trials. In addition, the collaboration will enable characterizing the molecular trajectory of natural disease courses and differential drug effects, which promises to deepen the IBD field’s understanding and treatment of these diseases by leveraging AI and large-scale molecular and clinical datasets. https://lnkd.in/dhP4uv9M #PrecisionMedicine #Innovation #IBD #InflammatoryBowelDisease #Autoimmunity #ArtificialIntelligence #SystemsMedicine #SystemsBiology #DataSciences #DrugDiscovery #DrugDevelopment #Medicine #Inflammation #IMID #Pharma #Biotech #Diagnostics
4
-
Jennifer Lovick, PhD
‼️ New article alert! Check out this detailed review, Molecular Biomarkers and Signaling Pathways of Cancer Stem Cells in Colorectal Cancer, from Omran et al., Helwan University, Egypt https://lnkd.in/gPsfJydi #crc #csc #stemcells #tumorbiology #cancerdiagnosis OncoDaily
1 Comment -
Hanson Wade Group
Do you work in the cell therapy❓- 𝗧𝗼𝗱𝗮𝘆 𝗶𝘀 𝘆𝗼𝘂𝗿 𝗙𝗜𝗡𝗔𝗟 𝗖𝗛𝗔𝗡𝗖𝗘 to 𝘀𝗲𝗰𝘂𝗿𝗲 𝗼𝘂𝗿 𝗵𝗶𝗴𝗵𝗲𝘀𝘁 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝘀 𝗼𝗳 𝘂𝗽 𝘁𝗼 $𝟭,𝟭𝟬𝟬 - https://ter.li/t2kq70 for the 𝟲𝘁𝗵 𝗠𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲-𝗗𝗶𝗿𝗲𝗰𝘁𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗦𝘂𝗺𝗺𝗶𝘁! This is a once-a-year opportunity to 𝗰𝗼𝗻𝗻𝗲𝗰𝘁 𝘄𝗶𝘁𝗵 𝗸𝗲𝘆 𝗽𝗹𝗮𝘆𝗲𝗿𝘀 from Carisma Therapeutics, ALX Oncology, NextPoint Therapeutics, Inc., Elpiscience Biopharmaceuticals, and more to unleash the full potential of your macrophage therapeutics and stay ahead of the curve.🤝 We also offer 𝗮𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗴𝗿𝗼𝘂𝗽 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝘀 𝗼𝗳 𝘂𝗽 𝘁𝗼 𝟮𝟬%, which you can explore in our full agenda - https://ter.li/9vo845 Don't let this valuable opportunity slip away! 𝗕𝗼𝗼𝗸 𝗯𝗲𝗳𝗼𝗿𝗲 𝗺𝗶𝗱𝗻𝗶𝗴𝗵𝘁 𝘁𝗼 𝘀𝗮𝘃𝗲 $𝟭,𝟭𝟬𝟬, and make a real impact this year at the #MacrophageDirectedTherapiesSummit
-
Randall Stanicky
I just arrived in rainy Boston to join my friends Dr. D. Martin Alexander Gershon, MD, JD, MPH MPH and Rebecca Miksad, MD, MMS, MPH to participate on a panel to discuss a topic most of us in the healthcare world are focused on - and a big focus of ours at Click Therapeutics: Playing the Long Game: The Roadmap to Integrate AI into the Healthcare System Groundbreaking new technologies such as AI, Machine Learning, Deep Learning are intersecting with unprecedented advances in healthcare and life sciences research, dramatically reshaping drug discovery, drug development and personalized medicine. There's been $100 billion in investments by Big Tech in AI innovation and technology in healthcare and life sciences in the past few years. While tech giants are driving innovation and supporting emerging AI companies with billions of dollars of investment, hospital systems and emerging companies alike are finding it very difficult to navigate the complexities of AI integration into the healthcare system. This discussion will bring together thought leaders from hospitals, the pharmaceutical industry, academia and emerging unicorns to look at the roadmap to integrate AI technologies into the healthcare system https://lnkd.in/guggF3Jh
33
2 Comments -
Serhat Pala
We at NuFund Venture Group are excited to announce our recent investment in Papillon Therapeutics a clinical-stage biotechnology company heralding a new era in genetic medicine for multi-systemic diseases. 🌍💉 🔬 Why Invest? Papillon, originating from the innovative ecosystem of UC San Diego, showcases groundbreaking approaches in the treatment of severe genetic disorders. Their use of gene-modified hematopoietic stem cells to potentially reverse disease symptoms across various organs not only challenges existing medical paradigms but provides a strong investment thesis to back transformative science. 🧬 •Papillon’s innovative technology addresses critical unmet needs that could significantly enhance quality of life and longevity for patients suffering from debilitating genetic disorders. •The early validations set a precedent for what the technology can achieve. •The potential for high-impact outcomes makes Papillon a perfect example of the type of company we aim to support. 🛡️ NuFund Deal Team for Papillon Therapeutics: • Meredith Fidler Ph.D., lead the deal for the NuFund Venture Group team with her extensive background in gene therapy and clinical science, making her uniquely qualified to spearhead this initiative. • Jeffrey Friedman and Robert Hess bring critical expertise in early-stage biotech development and intellectual property strategy, respectively. Their contributions have helped shape our investment framework, ensuring that we support ventures with robust scientific and commercial prospects. • Adam Pavlicek and Dean Gesme were instrumental in evaluating the scientific nuances and the strategic fit of Papillon within our portfolio. 💡 NuFund’s Unique Early Investor Approach: At NuFund, we pride ourselves on not just funding, but fostering innovation. Our unique approach as early-stage investors involves: • Deep Domain Expertise: Our team’s profound technical knowledge and industry experience empower us to discern and nurture potential breakthroughs. • Founder-Fair Support: We provide more than capital. Our hands-on guidance helps startups navigate the treacherous waters of biotech innovation, ensuring they are investment-ready. • Strategic Network: We leverage our extensive network within the San Diego ecosystem and beyond to provide startups like Papillon with the resources they need to succeed. 🌐 Follow NuFund Venture Group on LinkedIn to stay updated on how our partnerships are making a difference for the founders of innovative high growth early stage startups nationwide. Explore more about our innovative approach and why top-tier startups choose NuFund Venture Group at www.NuFund.com #SeedFunding #VentureCapital #DigitalHealth #EarlyInvestor #GeneticMedicine #Medtech #UCSD #SanDiegoStartup https://lnkd.in/gfgU9Dvj
69
-
Beth Rogozinski
I <3 Jon Campbell takeaways and agree completely! I'll also add that, regardless of commercial failures in the space, #digital #medicine is here to stay and is really the only hope we have of fixing a broken healthcare system. Additionally, we'll see #AI/ML increasingly being utilized in healthcare to advance early access and equity and improve outcomes.
3
-
Anthony Nolan: Cell Therapy and Laboratory Services
New research from the Dana-Farber Cancer Institute has used CRISPR to discover a new potential therapeutic target for the treatment of Acute Myeloid Leukaemia (AML). The researchers used genome-wide CRISPR interference to search for genes involved in AML cell metabolism, and discovered a subset of leukaemic cells that relied on phosphoinositide-3-kinase-gamma (PI3Kγ) signalling for energy production. A PI3Kγ inhibitor already exists – eganelisib – although has not yet been used to treat leukaemia. Here, the researchers effectively shrank AML tumour xenografts with eganelisib, and also found that eganelisib worked even more effectively in combination with the standard AML treatment cytarabine. These findings point towards eganelisib as being an attractive option to improve survival in AML patients, as it is an already existing drug that can be used in combination with cytarabine. The team is now designing a clinical trial to test this. CRISPR is continuing to contribute to major discoveries like this one. At Anthony Nolan, our Immunotherapy Group are investigating potential new cell therapies with the help of technologies like CRISPR. Learn more about how you can work with us: https://lnkd.in/eUX92NSS Read more about the study from the Dana-Farber Cancer Institute: https://lnkd.in/e6CuaMYs #AML #CRISPR
12
-
Moises Cepeda
New Post: Chips 2.0 for biomanufacturing, and other big ideas from MassBio conference -Speakers at MassBio’s conference focused on how despite industry headwinds and global challenges, Massachusetts has remained a global biotech leader — and highlighted the ways Massachusetts still needs to evolve to stay ahead. Source link Speakers at MassBio’s conference focused on how despite industry headwinds and global challenges, Massachusetts has remained a global biotech leader — and highlighted the ways Massachusetts still needs to evolve to stay ahead. Source link
-
Moe Alsumidaie
Precision BioSciences, Inc. has regained control of three gene editing programs from Prevail Therapeutics, a subsidiary of Eli Lilly. The programs utilize Precision’s ARCUS platform for gene editing applications, including excision and insertion. The collaboration between Precision and Prevail resulted in significant advancements for three programs, including proof-of-concept data for gene excision and insertion. Precision intends to independently develop or partner with others to advance these programs, capitalizing on the unique capabilities of the ARCUS platform. Regaining control of these programs does not affect Precision’s near-term clinical priorities in OTC deficiency, HBV, and PMM. The company’s cash runway remains sufficient to achieve these clinical milestones. Precision’s decision to focus on developing these programs independently or with partners reflects its commitment to delivering gene editing therapies for genetic diseases. #PrecisionBioSciences #GeneEditing #ARCUSplatform #PrevailTherapeutics #EliLilly #DMD #nonhumanprimates #geneticdiseases Michael Amoroso Jeff Smith
2
-
Siva Nadarajah
Congratulations and good luck to Sanket Shah for launching Otsuka Precision Health, Inc. (OPH). With FDA's new PDURS framework, we are confident a playbook will evolve for molecules and digital medicine to co-exist. It's hard to dismantle molecules from digital medicine. Keeping that in mind, we always conducted our clinical trials to show how JOGO Health + pills provide better outcomes. In one of the clinical trials, we demonstrated that adding JOGO to migraine medications improved MIDAS(Migraine Disability Assessment) score significantly. Another trial demonstrated JOGO's foundational science reduced side effects of cancer medications and medication discontinuation. pill + bytes is where digital medicine is heading.
29
-
Brad Power
How can you use cutting edge molecular analysis of a patient's cancer to develop a personalized treatment plan? Brian McCloskey is an advanced prostate cancer patient who may have received the most testing of anyone on the planet over his eight years of treatment. With help from the diagnostics company BostonGene, he recently had extensive testing done (whole genome DNA sequencing, RNA sequencing, and multiplex immunofluorescence), which identified new biomarkers (such as VEGF), characterized the microenvironment around his tumors (fibrotic), and compared these test results with his previous test results to uncover evolutionary divergence between his original tumor and new metastatic tumors. Brian's doctor Rana McKay, a leading oncologist at UCSD, then used these test results and a review of data on treatment options to arrive at a very personalized treatment plan: a two-drug combination available through a clinical trial. One drug (cabozantinib) targets one of his biomarkers (VEGF) and the other is an immune checkpoint inhibitor drug (nivolumab, brand name Opdivo). This combination has shown good efficacy in other cancers with a similar genomic profile. For more, please see here: https://lnkd.in/eWVfGGk9
15
-
Tufts Center for the Study of Drug Development
Tufts Center for the Study of Drug Development has partnered with Digital Medicine Society (DiMe) on the DATAcc by DiMe’s new project, “Building the Business Case for Digital Endpoints." This project will increase investment in digital measurement development and deployment in clinical trials by developing a value framework, industry benchmarking tools, ROI forecasting models, and a modular template business case framework to support innovators across the field to invest in digital endpoints and advance their broad adoption and scale in clinical research. To learn more about this project, visit https://bit.ly/3VuPALY Tufts CSDD's Joseph DiMasi and Zachary Smith are continuing with an advisory role on the project and have collaborated with CSDD's Abigail Dirks, MS, Ken Getz, and other industry leaders at Johnson & Johnson, Roche, Genentech, UCB, Bayer, Takeda and MindMed on research "Assessing the Net Financial Benefits of Employing Digital Endpoints in Clinical Trials". To access the research article, visit https://bit.ly/3X3NeEW #digitalendpoints #clinicaltrials #research
23
1 Comment -
Noubar Afeyan
My fellow panelists at the Milken Institute Global Conference made excellent points, especially these: we are in the early era of the "exponential curve" that will accelerate drug discovery with the help of AI, and it is going to take whole new models and innovative approaches to take maximum advantage of the potential. Great write up:
183
1 Comment -
Andrew Frye
Live your passion, Andy Mehrotra! For anyone keen to understand how AI gets used in workflow unification, midway this conversation gets serious. There are tons of leaders and project management tools, but this is unique. I sat through endless PPT hours only to be told "we'll look into this for the next meeting". @Unipr brings enterprise transparency and AI in a new way!
9
-
Andrii Buvailo, Ph.D.
Merck taps AI-focused biotech for new ADC pact worth $376M Biolojic Design, Ltd., a biotechnology company that uses computational biology and artificial intelligence (AI) to transform antibodies into programmable, intelligent medicines, today announced that it has entered into a multi-target drug discovery collaboration with Merck KGaA, Darmstadt, Germany. The partnership will leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders. Under the terms of the agreement, Biolojic Design will receive a low double-digit million euro upfront payment and research funding from Merck. It will also be eligible for drug discovery, development, regulatory and commercial milestone payments that may total up to €346 million. Biolojic Design will also be eligible to receive tiered royalties on net product sales. #biotech #antibodies #artificialintelligence #biopharmatrend Image credit: Biolojic Design
59
9 Comments -
Prenosis
🎬 Prenosis CEO Bobby Reddy, Jr., Ph.D., will appear on today’s NewsNation Now with Nichole Berlie at 12:45pm EST to discuss the groundbreaking Sepsis ImmunoScore™—the first-ever FDA-authorized AI diagnostic tool for sepsis. The Sepsis ImmunoScore™ is an innovative AI software as a medical device (AI SaMD) designed for sepsis detection and prediction. 👏 Sepsis, a challenging and often fatal condition, has long plagued the U.S. healthcare system, claiming more lives annually than all cancers combined. Reddy will also cover Prenosis’ precision medicine approach in acute care and its recent collaboration with Roche, alongside celebrating the FDA milestone. To watch: JoinNN.com #HealthTech #AIHealthcare #PrecisionMedicine #MedicalInnovation #FDAApproval #SepsisAwareness #HealthcareTechnology #MedicalDevices #ArtificialIntelligence #HealthcareInnovation #AcuteCare #RocheCollaboration #NewsNationNow #SepsisDetection #MedicalResearch #HealthcareTechnology
25
-
George Hartoularos, PhD
Single-cell and spatial transcriptomics friends: it'd be tremendously helpful to our team if you could briefly chat about your current unmet needs in this quickly-evolving space (no pun intended!) and gauge the value of the technologies we're developing. Please DM if you'd like to participate!
11
2 Comments -
Janis Naeve
Justin Klein, MD, JD is one of the best medtech VCs I know so when he says read something— I do. My favorite line— “Write an investment story—how the VCs will make money off the product”. This focus is necessary because it aligns the investors and management team with a clear line-of-sight for execution, hiring, capital raise, KPIs, etc. This advice doesn’t just apply to medtech investing btw…. Justin- thanks for sharing.
26
1 Comment
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More